Lawrence Kenyon

Interim Chief Executive Officer, CFO, Treas & Sec'y at Outlook Therapeutics.

Raised on Outlook Therapeutics filings

No sales reported yet

of $37M offered across 2 Form D filings

Company

Biotech · Iselin, NJ

Ophthalmic bevacizumab for wet macular degeneration

Ophthalmic bevacizumab for wet macular degeneration

Outlook Therapeutics Form D filings
Filed	Security	Sold of offered	Filing
May 7, 2026	Equity	None sold/ $5M	Form D
Jan 27, 2025	Equity	None sold/ $32M	Form D

Also named on Outlook Therapeutics filings